Literature DB >> 8527114

Evaluating psychotropic drugs in people with mental retardation: where are the social validity data?

A Poling1, M LeSage.   

Abstract

In general, social validity data reflect the social significance of target behaviors, the appropriateness of procedures, and the perceived importance of results. These data are important insofar as they predict whether a given intervention will be used and, if used, whether consumers are likely to be satisfied with it. Despite the importance of social validity data, a survey of articles published from 1987 through 1993 in five major journals revealed that none of the 68 articles concerned with the psychopharmacology of mental retardation reported social validity data.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8527114

Source DB:  PubMed          Journal:  Am J Ment Retard        ISSN: 0895-8017


  3 in total

1.  Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression.

Authors:  E Victoria Rundberg-Rivera; Lisa D Townsend; Jayne Schneider; Cristan A Farmer; Brooke B S G Molina; Robert L Findling; Kenneth D Gadow; Oscar G Bukstein; L Eugene Arnold; David J Kolko; Kristin A Buchan-Page; Nora K McNamara; Chenel Michel; Adrienne Austin; Heidi Kipp; Robert R Rice; Michael G Aman
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-04       Impact factor: 2.576

2.  Parent satisfaction in a multi-site acute trial of risperidone in children with autism: a social validity study.

Authors:  Elaine Tierney; Michael Aman; David Stout; Krista Pappas; L Eugene Arnold; Benedetto Vitiello; Lawrence Scahill; Christopher McDougle; James McCracken; Courtney Wheeler; Andres Martin; David Posey; Bhavik Shah
Journal:  Psychopharmacology (Berl)       Date:  2006-11-23       Impact factor: 4.530

3.  DHA ameliorates MeHg‑induced PC12 cell apoptosis by inhibiting the ROS/JNK signaling pathway.

Authors:  Hong Zhang; Susu Wang; Yaqian Wang; Anxin Lu; Chunping Hu; Chonghuai Yan
Journal:  Mol Med Rep       Date:  2021-06-10       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.